Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Heatmap
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
CLDX
#4232
Celldex Therapeutics, Inc. - Common Stock
0.3
1
USD
-0.85%
Sector:
Healthcare
Base:
USD
Profit Currency:
USD
Daily Range
Year Range
Daily Change
-0.85%
Monthly Change
-99.04%
6 month change
-98.82%
Year Change
-98.85%
Previous Close
0.3
2
Open
0.3
1
Low
0.3
1
High
0.3
1
Volume
136
Markets
US Stock Market
Healthcare
CLDX
Open full chart
Full chart
Financials
Overview
Statement
Statistics
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
Current
Key stats
Total common shares outstanding
39.61 M
46.74 M
47.21 M
55.9 M
66.38 M
66.57 M
78.49 M
Valuation ratios
Enterprise value
650.21 M
1.77 B
2.02 B
2.22 B
1.65 B
1.78 B
2.4 B
Price to earnings ratio
—
-23.56
-18.08
-13.84
-10.31
-6.96
-7.28
Price to sales ratio
—
0.36
0.86
0.28
0.23
1 167.65
2.83
Price to cash flow ratio
—
-0.03
-0.02
-0.02
-0.01
-8.55
-0.02
Price to book ratio
—
0
0.01
0
0
3.42
0
Enterprise value to EBITDA ratio
-10.94
-25.91
-17.97
-14.68
-8.59
-6.26
-7.86
Profitability ratios
Return on assets %
-0.25
-0.16
-0.24
-0.2
-0.13
-0.44
-0.15
Return on equity %
-0.29
-0.17
-0.26
-0.21
-0.14
-0.49
-0.17
Return on invested capital %
-483.12
-711.84
-937.82
-1 040.56
-1 165.13
-2 249.4
—
Gross margin %
97.3
97.85
95.76
95.64
97.15
87.06
100
Operating margin %
-854.06
-1 531.78
-4 889.01
-2 245.27
-2 778.89
-18.6 K
-562.9 K
EBITDA margin %
-801.09
-1 465.81
-4 766.14
-2 201.57
-2 733.63
-18.38 K
-557.21 K
Net margin %
-805.88
-1 516.04
-3 616.25
-1 331.85
-1 462.49
-16.75 K
-524.57 K
Liquidity ratios
Quick ratio
—
—
—
—
—
—
—
Current ratio
13.93
24.86
17.07
13.87
18.91
10.49
8.92
Inventory turnover
—
—
—
—
—
—
—
Asset turnover
0.04
0.01
0.01
0.02
0.01
0
0
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
—
-1 420.78
-2 212.34
-2 214.51
-2 450.16
-3.18
-1 396.88
EBIT per share
—
-1 661.84
-2 457.64
-3 189.79
-3 029.4
-4.33
-2 072.77
EBITDA per share
—
-1 590.27
-2 395.88
-3 127.7
-2 980.06
-4.28
-2 047.19
Total debt per share
—
—
—
—
—
—
—
Cash per share
—
9 522.98
6 503.84
8 743.17
11.26 K
7.81
6.78
Net current asset value per share
—
9 583.37
6 775.57
8 910.26
11.6 K
8.05
6.9
Tangible book value per share
—
9 784.84
6 957.09
8 858.2
11.6 K
7.53
6.45
Working capital per share
—
9 197.83
6 378.67
8 267.83
10.99 K
7.28
6.13
Book value per share
—
9 784.84
6 957.09
8 858.2
11.6 K
7.94
6.85
News
Celldex Therapeutics (CLDX) Reports Q1 Loss, Misses Revenue Estimates
Innoviva (INVA) Tops Q1 Earnings Estimates
Wall Street Analysts See a 76.42% Upside in Celldex (CLDX): Can the Stock Really Move This High?
Celldex Therapeutics stock hits 52-week high at $31.36
Celldex presents phase 2 data for chronic urticaria treatment
Celldex Therapeutics Stock Earns 88 RS Rating
Celldex Therapeutics earnings missed by $0.21, revenue fell short of estimates
Celldex Therapeutics stock hits 52-week high at 30.66 USD
Stifel reiterates Celldex Therapeutics stock rating on trial progress
Celldex completes Phase 3 enrollment for CSU treatment ahead of schedule
Celldex stock rating reiterated as Overweight by Cantor Fitzgerald
Celldex Therapeutics Stock Gets RS Rating Lift